CCR2 antagonist peptides
The invention relates to a peptide useful as a CCR2 non-competitive antagonist peptide.
1. A peptide which consists of
X1-TFLK-X3 (SEQ ID NO:18), wherein X1 is glycine or represents an amino acid sequence selected from the group consisting of AG, LG, YLG, and HYLG (SEQ ID NO: 30); and X3 independently is absent, or is alanine,
wherein the peptide possesses CCR2 antagonist activity.
2. The peptide of claim 1 , selected from the group consisting of
(SEQ ID NO: 19)
LGTFLK,
(SEQ ID NO: 21)
LGTFLKA,
(SEQ ID NO: 22)
GTFLK, and
(SEQ ID NO: 23)
AGTFLKA
3. The peptide of claim 1 , wherein all or part of the amino acids are in D configuration.
4. The peptide of claim 1 , wherein all or part of the amino acids are in L configuration.
5. A compound that comprises a peptide as defined in claim 1 linked to at least one non-peptide moiety.
6. The compound of claim 5 , wherein the non-peptide moiety is polyethylene glycol.
7. A pharmaceutical composition, comprising the peptide as defined in claim 1 , in association with a pharmaceutically acceptable carrier.